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Abstract 
      The FOXO3a and FOXM1 forkhead transcription factors are key players in cancer initiation, 
progression, and drug resistance. Recent research shows that FOXM1 is a direct transcriptional target of 
FOXO3a, a vital downstream effector of the PI3K-AKT-FOXO signaling cascade. In addition, FOXM1 and 
FOXO3a also antagonize each other’s activity by competitively binding to the same target genes, which are 
involved in chemotherapeutic drug sensitivity and resistance. Understanding the role and regulation of the 
FOXO-FOXM1 axis will provide insight into chemotherapeutic drug action and resistance in patients, and 
help to identify novel therapeutic approaches as well as diagnostic and predictive biomarkers.
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      Cancer is a widespread disease and a major cause 
of death worldwide. In 2008, 12.7 million new cases 
and 7.6 million deaths were reported[1]. Although novel 
therapeutics have improved patient survival rates, 
resistance to conventional anticancer drugs remains 
the principal reason for treatment failure, relapse, 
and cancer mortality. Patients for whom hormone 
or molecular-targeted therapies are not an option 
usually receive cytotoxic chemotherapeutic agents, 
including taxanes (e.g., paclitaxel and docetaxel) and 
anthracyclines (e.g., epirubicin and doxorubicin)[2]. For 
example, anthracyclines and taxanes are usually used 
as first- and/or second-line option(s) in chemotherapeutic 
regimens for patients with advanced or metastatic 
breast cancer or those with EGFR/HER2-negative and 
estrogen receptor (ER)-negative tumors. In most cases, 
these patients eventually become insensitive to taxane- 
and anthracycline-based chemotherapy and develop 
recurrent cancer, despite an initial response to these 
cytotoxic and genotoxic therapies.
Anthracyclines block RNA and DNA synthesis, 
tr iggering DNA damage through interfering with 
topoisomerase II and inducing the formation of reactive 
oxygen species. Taxanes, however, act specifically 
during the G2/M phase of the cell cycle, blocking cell 
cycle progression by impairing centrosome formation, 
induc ing abnormal  sp ind les ,  and suppress ing 
microtubule dynamics during spindle development. 
Although these drugs’ mode of action is known, the 
molecular mechanisms by which drug-resistant cancer 
clones evade their cytotoxic or genotoxic effects remain 
largely undefined[2,3].
FOXO-FOXM1 Axis in Tumorigenesis
and Drug Resistance
      Forkhead box (FOX) proteins belong to a 
superfamily of transcription factors defined by their 
highly evolutionarily conserved “winged-helix” DNA- 
binding domain (DBD). FOX proteins are responsible 
for the spatio-temporal regulation of a wide range 
of transcript ional programs required for normal 
homeostasis and development[4]. These FOX-regulated 
biological processes include cell proliferation, cell cycle 
progression, cell differentiation, tissue homeostasis, 
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Figure 1. Integration of intracellular and extracellular signals with the forkhead box class O3a (FOXO3a) and forkhead box protein 
M1 (FOXM1) axis. Intracellular and extracellular signals converge on the PI3K-AKT-FOXO3a-FOXM1 signaling cascade. FOXO3a 
antagonizes the transcription output of FOXM1, which controls cancer-related processes including proliferation, survival, drug 
resistance, angiogenesis, migration, and DNA damage repair. EGFR, human epidermal growth factor receptor; HER-2, human epidermal 
growth factor receptor 2; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; P38, P38 mitogen-activated protein 
kinase; P53, tumor suppressor protein 53; E2F, E2F transcription factor; ER, estrogen receptor; E2, estradiol; ATM, ataxia telangiectasia 
mutated protein; Ub, ubiquitination; P, phosphorylation.
angiogenesis, and apoptosis. As a result, it is not 
surprising that deregulation of FOX transcription factors 
can lead to severe pathologic conditions, including 
cancer. The forkhead box class O (FOXO) subfamily of 
transcription factors (i.e., FOXO1, FOXO3a, FOXO4, 
and FOXO6) act downstream of the phosphoinositol-
3-kinase (PI3K)-AKT oncogenic signaling cascade 
(Figure 1), and are required for the execution of diverse 
cellular functions, including cell cycle arrest, apoptosis, 
development, differentiation, invasion, metabolism, 
migration, and resistance to oxidative stress and DNA 
damage[4-8]. 
The PI3K-AKT cascade is a commonly deregulated 
signaling pathway in cancer. During tumorigenesis 
and the evolution toward cancer drug resistance, 
this oncogenic pathway is frequently hyperactivated, 
leading to FOXO inactivation. Overexpression of 
receptor tyrosine kinases, loss of function mutations 
within phosphatase and tensin homolog (PTEN), and 
activating mutations within PIK3CA (p110α) and AKT 
all result in increased AKT activity, which promotes 
tumor survival and cancer progression. Moreover, 
enhanced AKT activity also confers resistance to 
endocrine and molecular-targeted therapeutics as well 
as conventional cytotoxic and genotoxic drugs, further 
highlighting the importance of the PI3K-AKT signaling 
pathway and FOXOs in determining the outcome of 
drug sensitivity. Although it is well established that AKT-
growth factors
ERK
P38
P53
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mediated phosphorylation of FOXO proteins induces 
their cytoplasmic translocation and degradation, 
FOXOs—in particular FOXO3a—are also regulated by 
the extracellular signal-related kinase (ERK)/mitogen-
activated protein kinase (MAPK) and IκB kinase (IKK) 
pathways[4]. Crosstalk of these frequently deregulated 
signaling cascades culminates in the inactivation of 
the tumor suppressive function of FOXO3a. Emerging 
evidence has revealed that the cytostatic and cytotoxic 
effects of many anticancer therapeutics, including 
paclitaxel[9,10], doxorubicin[11,12], lapatinib[13], gefitinib[14,15], 
imatinib[16-18], cisplatin[19], and tamoxifen[4], are mediated 
through FOXO activation, primarily through inhibition of 
the PI3K-AKT signaling axis. In addition, in response 
to cytotoxic anticancer agent treatment, FOXO3a is 
targeted by the stress-activated MAPKs, including JNK 
and P38. For instance, JNK has been shown to induce 
FOXO3a activity and nuclear localization by repressing 
AKT phosphorylation and activity following paclitaxel 
treatment[9,10]. Moreover, P38 phosphorylates FOXO3a 
on Ser7, promoting FOXO3a nuclear relocalization and 
activation in response to doxorubicin[20]. Together these 
findings suggest that chemotherapeutic drugs integrate 
their signals with FOXO3a to mediate their effects 
primarily through the PI3K-AKT, ERK, JNK, and P38-
MAPK signaling pathways.
For all “good” FOX proteins, there is always a 
“bad” cousin. While the FOXOs are bona fide tumor 
suppressors, another closely related forkhead subfamily 
member, forkhead box protein M1 (FOXM1), behaves 
like a classic oncogene. The FOXM1 transcription factor 
has a central function in cell cycle progression and 
cell proliferation. As such, Foxm1-deficient mice die in 
utero due to a failure to enter mitosis[4,21]. Consistent 
with its role in proliferation, FOXM1 overexpression 
has been identified in many types of cancers, including 
liver, prostate, breast, lung, and colon cancers[4,22]. This 
was further confirmed by independent gene expression 
profiling studies of cancers, which identified FOXM1 as a 
commonly up-regulated gene in human solid tumors[22-24]. 
These findings suggest a key role for FOXM1 in 
tumorigenesis. In addition to cell proliferation, FOXM1 
controls and influences other biologic processes, 
including cell differentiation, apoptosis, angiogenesis, 
senescence, tissue homeostasis, and DNA damage 
repair[4,21]. Not surprisingly, there is a remarkable 
correlation between increasing levels of FOXM1 and 
progressive stages of human cancers.
Consistent with a role in tumor initiation and 
progression, FOXM1 has also been shown to induce 
the expansion of stem cell compartments, resulting 
in hyperplasia during tumorigenesis. FOXM1 plays a 
part in cancer progression by inducing the expression 
of downstream targets that promote the stem cell and 
epithelial-to-mesenchymal transition (EMT) phenotypes, 
including the stem and mesenchymal cell markers ZEB1, 
ZEB2, Snail2, E-cadherin, and vimentin. Ultimately, 
FOXM1-mediated expression of these genes culminates 
in increased cell proliferation, self-renewal capacity, 
long-term viability, cell migration, angiogenesis, and 
drug resistance[25]. In addition, FOXM1-deficient cells 
also display polyploidy, aneuploidy, chromosome 
missegregation, and an increase in the number of 
DNA breaks, all of which highlight the importance 
of FOXM1 in safeguarding mitosis and genomic 
integrity[26,27]. The role of FOXM1 in the clinical context 
of drug responsiveness and resistance has also been 
studied[4,13,21,28]. Increased FOXM1 expression has been 
found to confer resistance to chemotherapeutic drugs, 
such as cisplatin and epirubicin, equip cancer cells with 
protective mechanisms against DNA damage-induced 
cell death, and disrupt mitosis/cytokinesis control[13,29,30]. 
Furthermore, these chemotherapy-resistant cancer cells 
also expressed higher levels of FOXM1 compared with 
drug-sensitive counterparts[13,29,30]. The ability of FOXM1 
to confer resistance to the genotoxic and cytotoxic drugs 
has been linked to its ability to activate the expression 
of target genes important for DNA damage response, 
including breast cancer type 2 susceptibility protein 
(BRCA2), X-ray repair complementing defective repair in 
Chinese hamster cells (XRCC1), exonuclease 1 (EXO1), 
polo-like kinase 4 (PLK4), polymerase (DNA directed), 
epsilon 2, accessory subunit (POLE2), and replication 
factor C4 (RFC4)[31-33]. How these cytotoxic and genotoxic 
agents regulate FOXM1 expression remains unclear. 
Nevertheless, recent research demonstrates that the 
p38 MAPK-MK2 signaling pathway is involved in the 
control of drug sensitivity, as well as E2F1 and FOXM1 
expression in response to epirubicin[3]. In addition, upon 
treatment with genotoxic agents, the checkpoint kinases 
Chk1 and Chk2 also phosphorylate and activate FOXM1. 
FOXM1 is also involved in sensitivity and resistance of 
endocrine-related cancers to hormone therapy. Because 
ERα and FOXM1 regulate each other’s expression, it 
is not surprising that FOXM1 also contributes to the 
development of resistance to endocrine therapy in breast 
cancer[34,35]. This reciprocal regulation culminates in a 
positive feedback mechanism that, when deregulated, 
can cont r ibute to  tumor igenesis  and hormone 
insensitivity in endocrine-related cancers. Furthermore, 
recent evidence suggests that the anti-proliferative role 
of ERβ1 in the development of breast cancer is mediated 
through competing with ERα in the regulation of FOXM1 
expression[36]. 
Interestingly, FOXO3a and FOXM1 compete for 
binding to similar DNA sequences and share a number 
of downstream target genes[37]. As a result, FOXO3a 
antagonizes the transcriptional output of FOXM1[37,38], 
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such that genes act ivated by FOXM1 are often 
repressed by FOXO3a[13,14,39] (Figure 2). For instance, 
FOXM1 activates whereas FOXO3a represses VEGF 
expression to control angiogenesis and migration in 
breast cancer cells[37]. Moreover, the antagonistic action 
between FOXO3a and FOXM1 is also extended to the 
FOXM1 gene, which is negatively regulated by FOXO3a 
but positively regulated by FOXM1 at the transcriptional 
level[13,14,39]. On the other hand, FOXO3a and FOXM1 
may cooperate to regulate ERα gene transcription in 
breast cancer cells[35], and this may have implications 
for the action of estrogens and anti-estrogens in cancer 
development and treatment. 
Summary and Future Perspectives 
      In summary, the FOXO3a-FOXM1 axis, which 
functions downstream of the PI3K-AKT oncogenic 
signaling pathway, is the target of many conventional 
genotoxic and cytotoxic chemotherapeutic drugs. The 
FOXO3a and FOXM1 transcription factors are also 
cellular targets of endocrine and molecular targeting 
anticancer agents. Genes activated by FOXM1 are 
commonly repressed by FOXO3a. The FOXO3a-FOXM1 
axis can modulate cancer initiation, progression, and 
drug resistance by regulating the expression of genes 
essential for cell proliferation, survival, self-renewal, 
migration, angiogenesis, cell cycle/checkpoint transition, 
and DNA damage repair. Given the key roles of FOXO 
and FOXM1 proteins in cancer, a better understanding 
of the mechanisms by which FOXO and FOXM1 are 
regulated, as well as a greater appreciation of their roles 
and downstream targets in cancer, will help to develop 
these proteins into reliable diagnostic markers and 
therapeutic targets for cancer.
Figure 2. Integration of signals with the FOXO3a-FOXM1 axis in chemotherapeutic drug response. Chemotherapeutic drugs have various modes 
of action but ultimately integrate signals with the FOXO3a-FOXM1 signaling axis. FOXO3a then antagonizes the expression of FOXM1 target genes, 
which control cancer-related processes, including cell cycle progression, cell proliferation, anti-oxidative stress, cell self-renewal, drug resistance, DNA 
damage repair, senescence suppression, angiogenesis, and migration. RTK, receptor tyrosine kinase; MAPK, mitogen-activated protein kinase; PI3K, 
phosphoinositol-3-kinase.
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